The abnormal expression of Annexin II (AnxA2, A2) has been associated with the development of tumors; however, its expression and function in multiple myeloma (MM) is less known. We compared the expression of AnxA2 in primary myeloma cells from MM patients with that in normal plasma cells from normal subjects and found that myeloma cells from patients had higher expression of AnxA2. Expression of AnxA2 was also significantly higher in MM cell lines U266 and RPMI8226, compared with other hematologic tumor cell lines. Transfecting U266 and RPMI8226 cells with the small interfering RNA (siRNA) that targets human AnxA2 led to significant downregulation of AnxA2 expression, which resulted in the decreased proliferation, invasive potential and increased apoptosis of U266 and RPMI8226 cell lines. Silencing AnxA2 gene by siRNA also inhibited the expression of pro-angiogenic molecules including VEGF-C, VEGF-R2, MMP-2, MMP-9, MT1-MMP and TIMP-2 in the two cell lines. Our data suggested that the AnxA2 is overexpressed in MM patients and myeloma cell lines U266 and RPMI8226, and that AnxA2 overexpression appeared to affect the proliferation, apoptosis, invasive potential and production of pro-angiogenic factors in MM cell lines U266 and RPMI8226.
SiRNA AnxA2 Multiple myeloma U266 RPMI8226
This is a preview of subscription content, log in to check access
We thank Z. Ma, L. Chen and L. Xie for their help in performing the experiments. We thank Dr. N. Dong for giving helpful discussion.
Zhan FH, Tian E, Bumm K, et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003;101:1128–40.CrossRefPubMedGoogle Scholar
Verdelli D, Mattioli M, Fabris S, et al. Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. Haematologica. 2005;90:1541–8.PubMedGoogle Scholar
Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther. 2007;6:802–10.CrossRefPubMedGoogle Scholar
MacLeod TJ, Kwon M, Filipenko NR, et al. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003;278:25577–84. doi:10.1074/jbc.M301017200.CrossRefPubMedGoogle Scholar
Semov A, Moreno MJ, Onichtchenko A, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation. J Biol Chem. 2005;280:20833–41. doi:10.1074/jbc.M412653200.CrossRefPubMedGoogle Scholar
Ortiz-Zapater E, Peiro S, Roda O, et al. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol. 2007;170:1573–84. doi:10.2353/ajpath.2007.060850.CrossRefPubMedPubMedCentralGoogle Scholar